cancer immunotherapy

German Merck Licenses Fusion Protein to PDS

Germany‘s Merck has granted an exclusive license for the tumor-targeting IL-12 fusion protein currently known as M9241 to PDS Biotechnology Corporation, a US-based clinical-stage immunotherapy company with a growing pipeline of targeted immunotherapies for cancer and infectious disease.

News

Merck, Ono To Jointly Develop Oral Multiple Sclerosis Drug, Cancer Immunotherapy

Top-Feature

INOSIM GmbH

Predictive Simulation in Pharma Production

JULABO GmbH

When Every Temperature Change Determines the Process

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.